Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;38(3):157-166.
doi: 10.1007/s40290-024-00520-3. Epub 2024 Apr 4.

Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings

Feng Sun  1   2 , Alexander Bedenkov  3 , Bi-Cheng Liu  4 , Jiefu Yang  5 , Jin-Fu Xu  6 , Linong Ji  7 , Min Zhou  8 , Shaosen Zhang  9 , Xinli Li  10 , Yuanlin Song  11 , Pingyan Chen  12   13 , Carmen Moreno  14
Affiliations

Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings

Feng Sun et al. Pharmaceut Med. 2024 May.

Abstract

Use of real-world data (RWD) is gaining wide attention. To bridge the gap between diverse healthcare stakeholders and to leverage the impact of Chinese real-world evidence (RWE) globally, a multi-stakeholder External Advisory Committee (EAC) and EAC meetings were initiated, aiming to elucidate the current and evolving RWD landscape in China, articulate the values of RWE in ensuring Chinese patients' equitable access to affordable medicines and solutions, and identify strategic opportunities and partnerships for expansion of RWE generation in China. Chinese and international experts who are clinicians and academic researchers were selected as EAC members based on their professional background and familiarity with RWD/RWE. Three EAC meetings were held quarterly in 2023. Various topics were presented and discussed for insights and suggestions. Nine experts from China, one from South Korea, and two from Europe were selected as EAC members and attended these meetings. Experts' presentations were summarized by theme, including the RWD landscape and RWE enablement in China, as well as global development of a patient-centric ecosystem. Experts' insights and suggestions on maximizing the RWD/RWE value to accelerate healthcare transformation in China were collected. We concluded that though data access, sharing, and quality are still challenging, RWD is developing to support evidence generation in the medicinal product lifecycle, inform clinical practice, and empower patient management in China. RWD/RWE creates value, accelerates healthcare transformation, and improves patient outcomes. Fostering a patient-centric ecosystem across healthcare stakeholders and maintaining global partnerships and collaboration are essential for unlocking the power of RWD/RWE.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
An overview of the objectives of three External Advisory Committee meetings. EAC External Advisory Committee, RWD real-world data, RWE real-world evidence
Fig. 2
Fig. 2
An overview of the crucial role of real-world evidence across the medicinal product lifecycle in China
Fig. 3
Fig. 3
An overview of Chinese real-world data opportunities to tackle challenges. RWD real-world data
Fig. 4
Fig. 4
A conceptual framework of real-world data (RWD) opportunity, real-world evidence (RWE) enablement, and RWD/RWE maximization via the patient-centric ecosystem in China
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. U.S. Food and Drug Administration. Real-World Evidence 2023. Available from: https://www.fda.gov/science-research/science-and-research-special-topics.... Accessed on 30 Jun 2023
    1. Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287. doi: 10.1186/s12874-022-01768-6. - DOI - PMC - PubMed
    1. Dang A. Real-world evidence: a primer. Pharmaceut Med. 2023;37(1):25–36. - PMC - PubMed
    1. Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295–304. doi: 10.2147/JMDH.S160029. - DOI - PMC - PubMed
    1. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600–606. doi: 10.7326/0003-4819-153-9-201011020-00010. - DOI - PubMed

LinkOut - more resources